Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices
In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. [Source]
Publication Date:Origin: nytimes.com
Category: Prices (Fares, Fees and Rates)
Topics: competition, blocked, aggressively, Amgen, drugmaker, tactics, patent, Using, arthritis, Enbrel, price, Colorado, first, Prices, State-Level, Target, Monopoly, 30-Year
Source: https://www.nytimes.com/2025/10/23/health/enbrel-arthritis-amgen-colorado-drugprices.html